December 5th Options Now Available For Moderna (MRNA)

Investors are presented with two options strategies for Moderna (MRNA) stock: selling a $23.00 put contract, which offers a potential 4.96% return (42.03% annualized) if it expires worthless with a 70% probability, effectively targeting a 13% discount on share acquisition. Alternatively, a covered call strategy utilizing a $29.00 strike call could yield a 15.93% total return if MRNA is called away, or a 5.95% premium boost (50.49% annualized) if the call expires worthless with a 58% probability. These strategies are framed against MRNA's implied volatilities of 107% for puts and 84% for calls, contrasting with its 66% trailing 12-month actual volatility.

Analysis

The article presents two distinct options strategies for Moderna (MRNA), currently trading at $26.37, designed to either acquire shares at a discount or generate enhanced yield. Selling a $23.00 strike put contract, with a bid of $1.14, offers a potential 4.96% return on cash (42.03% annualized) if it expires worthless, an event with a 70% probability. This strategy effectively sets a $21.86 cost basis for share acquisition, representing a 13% discount to the current market price.

Alternatively, a covered call strategy utilizing a $29.00 strike call, with a bid of $1.57, could yield a 15.93% total return if MRNA shares are called away by the December 5th expiration. If the call expires worthless, which has a 58% probability, the premium collected represents a 5.95% boost (50.49% annualized). These strategies are framed against MRNA's implied volatilities of 107% for puts and 84% for calls, notably higher than its 66% trailing twelve-month actual volatility.

The elevated implied volatilities relative to historical actual volatility suggest that options premiums are currently rich, potentially benefiting options sellers. While the put strategy offers a defined entry point and income, the covered call strategy caps upside participation if MRNA experiences a significant price appreciation beyond the $29.00 strike. The overall mildly positive sentiment and low market impact score indicate these are tactical considerations rather than reactions to major fundamental shifts.

Key Decisions for Investors

• Investors interested in acquiring MRNA shares at a discount could consider selling the $23.00 strike put, which offers a 4.96% premium (42.03% annualized) with a 70% probability of expiring worthless, effectively targeting a $21.86 cost basis.
• For existing MRNA holders seeking to enhance yield, selling the $29.00 strike covered call presents a potential 5.95% premium boost (50.49% annualized) if it expires worthless, or a 15.93% total return if shares are called away by December 5th.
• Given the implied volatilities (107% for puts, 84% for calls) are significantly higher than MRNA's 66% trailing actual volatility, investors should recognize that current options premiums are elevated, potentially favoring options sellers.
• While these strategies offer attractive yields, investors must weigh the capped upside potential of the covered call and the commitment to buy with the put against their fundamental outlook for MRNA, especially given its historical volatility.